A New Collaboration Could Bring A New CLN2 Batten Disease Treatment To Patients Faster

LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies have just announced their collaborative partnership. The aim is to develop and ultimately manufacture the AAV-mediated gene therapies developed by LEXEO.


LEXEO is a gene therapy company focused on AAV treatments. It is based out of New York City and focuses specifically on genetic cardiovascular diseases as well as central nervous system diseases. It does focus on both widespread genetic conditions and rare diseases.

Their current pipeline includes therapies for Alzheimer’s disease associated with APOE4, CLN2 Batten sisease, and rare cardiac conditions. In total, they have 15 current AAV programs.

FUJIFILM Diosynth Biotechnologies

This company is a manufacturing company focused on viral vaccines, vectors, and biologics. They are located in North Carolina, Texas, Denmark, the UK, and more. This company has been around for more than 30 years.

They have focused on vaccines, proteins, monoclonal antibodies, viral products, and more.

The Collaboration

This partnership between these two companies will ensure that therapies will get to patients faster. One company has gene therapy expertise and one company has expertise regarding development and manufacturing. Together, they can improve patient lives.

The first focus of this partnership will be the trial of LX1004 as a treatment for CLN2 Batten disease.

You can read more about this new collaboration here.

Share this post

Follow us